Trump’s Admin Taking Shape… And What To Expect Out Of Tomorrow’s CPI Report 11/12/24
CNBC's "Fast Money"
00:00
Market Analysis of Amgen's Stock and Obesity Drug Prospects
This chapter delves into Amgen's stock performance, focusing on the recent 7% decline and the implications of phase two data for its obesity drug. It highlights competitive challenges in the market and cautions investors about potential risks, including a looming patent cliff.
Play episode from 23:26
Transcript
